Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Author

Mariateresa Rossi

View on Semantic Scholar

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Current Challenges in Atopic Dermatitis: An Italian Delphi Consensus with a Special Focus on Moderate Disease.

INTRODUCTION Atopic dermatitis (AD) is a chronic, inflammatory skin disease clinically characterized by eczematous lesions and severe itch, significantly affecting the patients' quality of life. AD is classified as mild, moderate, or severe according to the extent and severity of these lesions. While therapeutic protoc...

A. Costanzo, A. Campanati, M. Esposito et al. · 0 citations
Review Open access Nov 2026

Treat-to-Target in Atopic Dermatitis: An Italian Survey and Expert Opinion on Clinical Practice and Unmet Needs.

INTRODUCTION Treat-to-target (T2T) strategies are increasingly used in atopic dermatitis (AD), although implementation remains heterogeneous in clinical practice. We aimed to investigate clinical practices, therapeutic priorities, and unmet needs in the long-term management of moderate-to-severe AD within a T2T framewo...

S. Ferrucci, M. Galluzzo, M. Guanti et al. · 0 citations
Open access Oct 2026

Cumulative Disease Control with Upadacitinib in Moderate-to-Severe Atopic Dermatitis-A 52-Week Multicenter Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis).

INTRODUCTION Fixed-timepoint endpoints may not fully capture longitudinal treatment benefit in atopic dermatitis (AD). We evaluated the 52-week real-world effectiveness and safety of upadacitinib, focusing on cumulative disease control. METHODS This multicenter retrospective analysis of prospectively collected LANDSC...

L. Potestio, M. Bianco, L. Mastorino et al. · 0 citations
Oct 2026

Upadacitinib for the Management of Atopic Dermatitis in Patients Aged ≥60 Years: A Long-Term Multicenter Real-World Study.

BACKGROUND Atopic dermatitis (AD) in the elderly is increasing worldwide and presents therapeutic challenges due to age-related comorbidities that often contraindicate systemic therapies. Although oral Janus kinase (JAK) inhibitors show efficacy in moderate-to-severe AD, older adult patients are underrepresented in cli...

E. Ippoliti, N. Gori, G. Coscarella et al. · 0 citations
Review Open access Oct 2026

Initiating Biologics in Atopic Dermatitis: Global Practices and Recommendations from the AMAZE Project.

INTRODUCTION Biologics have expanded treatment options for moderate-to-severe atopic dermatitis (AD), but practical guidance on how to initiate and manage these therapies in routine care remains limited. The advancing management of atopic dermatitis and eczema (AMAZE ) project examined global clinical practices and dev...

A. Armstrong, H. Kim, Andrew E. Pink et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.